We’re proud to bring you our coverage of the 2015 San Antonio Breast Cancer Symposium! Below you can find our coverage of breast cancer study results presented December 8-12, 2015 in San Antonio, TX. Keep checking this page for updates in Research News and podcasts with our experts!
[Editor’s Note: Updates will be added to the top of this page.]
Dec 22, 2015
Women diagnosed with early-stage, HER2-negative breast cancer with residual disease who were treated with Xeloda after surgery had better survival compared to women who didn’t get chemotherapy after surgery.
Dec 14, 2015
The TH3RESA study found that Kadcyla improved overall survival in women diagnosed with metastatic, HER2-positive breast cancer that had stopped responding to Herceptin and Tykerb compared to the women’s doctors’ treatment of choice.
Dec 12, 2015
Two studies presented at the 2015 San Antonio Breast Cancer Symposium looked at the effectiveness and side effects of Arimidex and tamoxifen to reduce recurrence risk after DCIS surgery and radiation in postmenopausal women. The studies found that the medicines reduced the risk of recurrence about the same amount, but there were differences in side effects.
Chief Medical Officer Marisa Weiss, M.D. talks about these studies:
Dec 10, 2015
Luminal A breast cancer is cancer that is estrogen-receptor positive and/or progesterone-receptor positive, HER2-negative, and has low levels of the protein Ki-67, which helps control how fast cancer cells grow. Research presented at the 2015 San Antonio Breast Cancer Symposium suggests that premenopausal women diagnosed with luminal A breast cancer have the same disease-free survival rates whether or not they receive chemotherapy after surgery.
Dec 10, 2015
Prolia is a targeted therapy used to treat bone loss in women taking aromatase inhibitors as part of their breast cancer treatment. A study presented at the 2015 San Antonio Breast Cancer Symposium has found that Prolia also reduced recurrence risk for postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer taking an aromatase inhibitor.
Dr. Marisa Weiss shares her perspective about this study:
Dec 10, 2015
Triple-Negative Disease May Have New Treatment Option
Two studies presented at the 2015 San Antonio Breast Cancer Symposium suggest that adding carboplatin to the standard presurgery chemotherapy regimen may improve outcomes for women diagnosed with triple-negative disease.
Dr. Marisa Weiss talks more about the first study:
Dr. Weiss also discusses the second study:
Dec 10, 2015
Lumpectomy Plus Radiation May Offer Survival Benefits for Early-Stage Disease
Many studies from the 1970s showed that lumpectomy plus radiation to treat early-stage breast cancer offered the same survival rates as mastectomy. So it was recommended that lumpectomy plus radiation be preferred over mastectomy to treat early-stage disease. Over the last several years, some studies suggested that lumpectomy plus radiation offered better survival than mastectomy for early-stage disease cancer, but the follow-up time was only 5 years. Now a study with 10 years of follow-up also suggests that lumpectomy plus radiation may offer survival benefits for some women diagnosed with early-stage disease.
Dr. Marisa Weiss explains what this means for you if you’re making surgery decisions:
Stay tuned to this page for more coverage on the way!
Traveltext says:
Any news for men with BC?
Rod